Evidence map›Paper›PMID 35300976›Full record

ReviewChest2022

Sex and Gender in Lung Disease and Sleep Disorders: A State-of-the-Art Review.

Amik Sodhi, Margaret Pisani, Marilyn K Glassberg, Ghada Bourjeily, Carolyn D'Ambrosio

Open access · greenAbstract readReview
In one paragraph

Review in Chest, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Sex, hormones, and lung health.Physiological reviews · 2026
    Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Sex and gender differences during the lung lifespan: unveiling a pivotal impact.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Amik SodhiDivision of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin, Madison, WI.
Margaret PisaniDivision of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT.
Marilyn K GlassbergDivision of Pulmonary, Critical Care and Sleep Medicine, University of Arizona College of Medicine Phoenix, Phoenix, AR.
Ghada BourjeilyDivision of Pulmonary, Critical Care and Sleep Medicine, Brown University, Providence, RI.
Carolyn D'AmbrosioDivision of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT. Electronic address: Carolyn.dambrosio@yale.edu.
Yale University · USBrown University · USUniversity of Arizona · USUniversity of Wisconsin–Madison · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Predictors of de novo development of obstructive sleep apnea in pregnancyR01HL130702 · NHLBI · MIRIAM HOSPITAL · PI BOURJEILY, GHADA · 2016 to 2020
$2.6M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL130702
6 · The paper itself

Abstract

The terms sex and gender often are used interchangeably, but have specific meaning when it comes to their effects on lung disease. Ample evidence is now available that sex and gender affect the incidence, susceptibility, presentation, diagnosis, and severity of many lung diseases. Some conditions are more prevalent in women, such as asthma. Other conditions are seen almost exclusively in women, like lymphangioleiomyomatosis. Some life stages-such as pregnancy-are unique to women and can affect the onset and course of lung disease. Clinical presentation may differ as well, such as higher number of exacerbations experienced by women with COPD and greater cardiovascular morbidity in women with sleep-disordered breathing. In addition, response to therapy and medication safety may also differ by sex, and yet, pharmacogenomic factors often are not addressed adequately in clinical trials. Various aspects of lung and sleep biology and pathobiology are impacted by female sex and female reproductive transitions. Differential gene expression or organ development can be impacted by these biological differences. Understanding these differences is the first step in moving toward precision medicine for women. This article is a state-of-the-art review of specific effects of sex and gender focused on epidemiology, disease presentation, risk factors, and management of lung diseases. Pathobiological mechanisms explaining sex differences in these diseases are beyond the scope of this article. We review the literature and focus on recent guidelines about using sex and gender in research. We also review sex and gender differences in lung diseases.

Indexed as

AsthmaLung DiseasesSleep Apnea SyndromesSleep Wake DisordersFemaleHumansLungMalePregnancySex FactorsasthmaCOPDgenderlung cancersexsleep-disordered breathing

Identifiers

PMID35300976
PMCPMC9808608
OpenAlexW4220663860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.